TrialClinical and translational science2022

Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168).

Timothy D Owens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.